What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma
About this episode
The episode discusses the role, efficacy, and safety of agents targeting BCMA in the care of patients with multiple myeloma after previous therapies.
This podcast includes a discussion on what oncology pharmacists need to know about the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy.
More episodes of Decera Clinical Education Oncology Podcast
- Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
- Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer
- Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
Explore listener stats, chart rankings, contacts and more on the Decera Clinical Education Oncology Podcast podcast page.